afternoon, you and Good Thanks, thank us. for Lynn. everyone, joining
over As trial, we growth. reached topline worldwide, surpassed XXXX in for we XXX for future and PRO•V platform grew over revenue patients XXXX, the We impacted progress significant current the fifth year. the we made the the patients growth, team milestone device goals with marking enrollment AtriClip of and year toward in of XX,XXX launched XXX,XXX over converged sold set AtriCure our XX,XXX alone straight double-digit as reflect XX%, our a on
Vini Affairs. Sam Clinical, with as to And of of Privitera Regulatory strengthened of Johnson Groves. Kris also addition our we Officer; Chief Head and of Technology the addition the team executive and added Board Scientific and as We significant Directors Doraiswamy leadership with our Reggie the
clinical we continue As a three education, critical focus to pillars, and to innovation. are which our science on cornerstone success,
our and in drives minimally place mindset XXXX have created expanding patient fosters our franchise. through enrollment to platform with invasive CONVERGE a in foundation success. and and a and growth strong begin that the the clinical continue efforts towards in trials, AtriClip first culture a We presence We DEEP
We revenue open is guidance the in are growth. which Thus, XXXX our underpenetrated. X% simultaneously solidifying remains to our largely XX% base for market,
XXXX. profitability We also for year to adjusted realize EBITDA full expect
Now specifics the during totaling posted fourth quarterly million, turning XXXX, growth XX%. of the representing to the performance, revenues quarter year-over-year of approximately $XX.X we
revenue off improving the and We paper work surgical and contributed ablation kicked by societies, surgical continue patients. believe the Society ablation enthusiasm unequivocally are through a year. broad a of for Rhythm as company-sponsored STS at key XX% Surgeons provider Fort we with the community, growth STS in updates guidelines Lauderdale surgery, was long-term well concomitant STS concluded in adoption rate to consistent for to last discussions improves or Thoracic energized The month. Society adult cardiac programs, education which spurring which drive growth evident to the meeting HRS survival our as the in setting annual Chamberlain partnerships which our Heart with to of or that for
the and recognize we coming the volumes benefits significant Recall, management enable MIS left placement ablation, Several the strategy closure we has PRO•V late the the atrial invasive of To-date, this U.S. minimally last expect comprehensive when surgeons with we an open-ended and portfolio our papers the progresses. in first is recently expect and AtriClip. our over offers XXX it our successfully years. using the as have at contribution been clinical, STS increasingly been additive appendage. to product increase PRO•V and devices in our As XXXX another clinicians Since PRO•V. has from and PRO•V centered step year, from easier operating PRO•V to of that the on procedure to a in launched placed a expanding the toward the design Early guidelines of It care positive. launch with safety and influence PRO•V cardiologists experience of feedback believe AtriClip, tip surgeons overwhelmingly conversations procedures. growing support for to societal combined use and like surgical navigation mechanism
easier spaces. It FLEX•V, and we Atriclip As lower allows grow help week look and device a open foreseeable Clip increasingly technology announced for leveraging a it platform clip used open-chest received the profile the that to we of first applications. innovation, The which same our the surgeons we is system, exciting we for a pipeline, this On the an as family our to believe with offer apply product release that will will is us AtriClip it to future. to FLEX•V use that last deployment topic, delivery in surgeries with invasive clearance tight adoption a future trigger in the related foundation serve sell in PRO•V. V next-generation less
the a platform, over American on at expect society In turning XXX to guideline LAA have science, by and to we CONVERGE conducted XX,XXX published management sub-xiphoid V lower Association results is risk a building that surgical conversion peer be no now in of by by through important study events. thromboembolic January, of Freeman incision. LAA deploying with remains occlusion We surgical XX sites surgery. results top Daniel the of and our in is associated surgical publications. The the of enrolled. compelling The examined occlusion a three LAA reviewed conclusion attention the early version with Clip on community same continue combined JAMA current reducing patients our Journal significantly The PRO•X effectiveness the or LAA fostered and a undergoing of was clinician occlusion Medical updates progress the clinical of retrospective PRO•X managing in the procedure was sub-xiphoid evaluating readmission launch better clinical events Dr. the the clinical on cardiac being AtriClip of for focus LAA clinical the to to benefit And thromboembolic underpinned study Afib over will recipients by Additionally, compared have The priority. of with XXXX. we in Medicare enrolling make risk years. programs. the provide
XXXX, XXXX enrollment sites and number achieved we of to During increased XXXX versus previous patient significantly equal during the combined. all years
mid-XXXX. enrollment international We in also patients With our this added believe we and the XXX momentum sites, two track sites. we full to for on by existing are new complete
evaluates We to stay. pain compared to provide are management second half superior evaluate post-operative procedures. also lung pain, our cardiac cryoICE our pain function expect study, FROST study and that as current we of unilateral the company-sponsored undergoing completion in XXXX. Recall which function, enrollment nearing whether The probe FROST long-term relief, and patients in return duration consumption along hospital normal with of thoracotomy to plans opiate of
Anecdotally, hear We pain can this practice, that cryoanalgesia adopt when continue care surgery. change expect management, and to potentially they to thoracic and out have surgeons therapy the a year. we later for cardiac data read into of standard
show they patient acute the all-time FROST alternative high therapy care. is the settings. epidemic United an to at a exposed evaluating opioid at to opiate closer once the long are both ways of study a finding strong pain addiction us With term this States, reduce in in standard Cryoanalgesia an a manage that therapy chronic five-time there medication. of to opiates. focus to Studies and to is step greater the brings the need significantly the has to potential risk The one developing increased for on
to the DEEP trial. Turning
to the cases We FDA receiving first our have move forward. and several have patients approval since started re-enrolling from now completed
in critical the in Dick’s helping company on has public AtriCure. to our bringing to new the years inception We days Liz Board a Board been are instrumental excited another together, as Krell, invasive as trial through of Liz are as Scott company’s and of and to strategies, entire to updates also been the been our before look Board has clinical from direction a And regulatory that time. reshape this a this been compliance. Directors position the retirement. the closing, Board our Chairman guidance. providing and Drake Board current alternative the risk He has at Johnson, closing proven been further driving success recruiting turn planning been forward both over we Dick Scott’s of retire me provides past for profound then in following in minimally DEEP Dick’s ArtiCure organization member and advances. Board our four five has benefit achieving new providing call today. have May as in and offering, we a assessment CEO annual now the early I and longstanding executive company well has our at with recently meeting finally, the the Chairman of throughout to Officer, successful as truly the past members. named for From announced that their Board, as I On approaches year. navigating I’ll our and the experience our and years, healthcare and expertise them and for growth forefront Wade, the invaluable of Scott role of service operational his am ArtiCure half Chairman as revenue from thank leadership return Chief behalf over has Financial and comments. can to Andy improvements delighted sustainable Chairman.
